Stinissen P - Search Results

1

Cytomegalovirus: a culprit or protector in multiple sclerosis?

Vanheusden M, Stinissen P, 't Hart BA, Hellings N. Vanheusden M, et al. Among authors: stinissen p. Trends Mol Med. 2015 Jan;21(1):16-23. doi: 10.1016/j.molmed.2014.11.002. Epub 2014 Nov 20. Trends Mol Med. 2015. PMID: 25500015

2

Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis.

Stinissen P, Medaer R, Raus J. Stinissen P, et al. Mult Scler. 1998 Jun;4(3):203-11. doi: 10.1177/135245859800400322. Mult Scler. 1998. PMID: 9762675 Review.

3

T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls.

Hellings N, Barée M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC, Raus J, Stinissen P. Hellings N, et al. Among authors: stinissen p. J Neurosci Res. 2001 Feb 1;63(3):290-302. doi: 10.1002/1097-4547(20010201)63:3<290::AID-JNR1023>3.0.CO;2-4. J Neurosci Res. 2001. PMID: 11170179

4

Insights into the immunopathogenesis of multiple sclerosis.

Hellings N, Raus J, Stinissen P. Hellings N, et al. Among authors: stinissen p. Immunol Res. 2002;25(1):27-51. doi: 10.1385/IR:25:1:27. Immunol Res. 2002. PMID: 11868933 Review.

5

Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity.

Hellings N, Gelin G, Medaer R, Bruckers L, Palmers Y, Raus J, Stinissen P. Hellings N, et al. Among authors: stinissen p. J Neuroimmunol. 2002 May;126(1-2):143-60. doi: 10.1016/s0165-5728(02)00052-8. J Neuroimmunol. 2002. PMID: 12020966

6

T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

Van der Aa A, Hellings N, Medaer R, Gelin G, Palmers Y, Raus J, Stinissen P. Van der Aa A, et al. Among authors: stinissen p. Clin Exp Immunol. 2003 Jan;131(1):155-68. doi: 10.1046/j.1365-2249.2003.02019.x. Clin Exp Immunol. 2003. PMID: 12519400 Free PMC article.

7

Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls.

Van der Aa A, Hellings N, Bernard CC, Raus J, Stinissen P. Van der Aa A, et al. Among authors: stinissen p. J Neuroimmunol. 2003 Apr;137(1-2):164-76. doi: 10.1016/s0165-5728(03)00048-1. J Neuroimmunol. 2003. PMID: 12667661

8

Effects of prolactin on cloned human T-lymphocytes.

Dogusan Z, Martens N, Stinissen P, Hellings N, Demotte N, Hooghe R, Hooghe-Peters E. Dogusan Z, et al. Among authors: stinissen p. Endocrine. 2003 Feb-Mar;20(1-2):171-6. doi: 10.1385/endo:20:1-2:171. Endocrine. 2003. PMID: 12668883

9

Immune-mediated oligodendrocyte injury in multiple sclerosis: molecular mechanisms and therapeutic interventions.

Buntinx M, Stinissen P, Steels P, Ameloot M, Raus J. Buntinx M, et al. Among authors: stinissen p. Crit Rev Immunol. 2002;22(5-6):391-424. Crit Rev Immunol. 2002. PMID: 12803318 Review.

10

Characterization of three human oligodendroglial cell lines as a model to study oligodendrocyte injury: morphology and oligodendrocyte-specific gene expression.

Buntinx M, Vanderlocht J, Hellings N, Vandenabeele F, Lambrichts I, Raus J, Ameloot M, Stinissen P, Steels P. Buntinx M, et al. Among authors: stinissen p. J Neurocytol. 2003 Jan;32(1):25-38. doi: 10.1023/a:1027324230923. J Neurocytol. 2003. PMID: 14618099

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

154 results

Search Page